Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Highmark Provides Pediatricians With Res To Combat Childhood Obesity
Childhood obesity causes lifelong illness, leads to serious health complications in young adults and can lead to premature death in adulthood due to medical conditions such as diabetes, heart disease and hypertension. In addition to its significant human toll, childhood obesity alone costs the nation"s health care system some $14 billion annually.

Celladon Provides MYDICAR(R) Program Update Of First-In-Human Trial For Advanced Heart Failure At American Society Of Gene Therapy Annual Meeting
Celladon Corporation presented today Phase 1 data from the Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID), a First-in-Human Phase 1/2 Clinical Trial, in a scientific symposium at the 12th Annual American Society of Gene Therapy Meeting.
News of the day
In Kidney Disease Caused By HIV, A Protein Excreted In Urine May Be Help In Diagnosis
New data collected at Columbia University Medical Center and by the Mount Sinai School of Medicine are helping researchers understand the extent to which a certain protein - NGAL - can play a significant role in marking chronic kidney disease resulting from HIV while at the same time distinguishing nephropathy from more common causes such as diabetes and hypertension.
Nutrition

Antigenics' QS-21 Adjuvant Enters Pivotal Phase 3 Clinical Trial Of GlaxoSmithKline's Malaria Vaccine

Antigenics Inc. (NASDAQ: AGEN) announced that GlaxoSmithKline (GSK) has launched a Phase 3 study with the world"s most clinically-advanced malaria vaccine, RTS,S, which contains Antigenics" QS-21 Stimulon® adjuvant. "There are now approximately 15 vaccines containing QS-21 in clinical trials of which four have now progressed into Phase 3 studies across multiple indications including non-small cell lung cancer, melanoma and malaria," said Garo H. Armen, PhD, chairman and CEO of Antigenics. "Today"s announcement demonstrates that QS-21 is a critical adjuvant in the development of therapeutic and prophylactic vaccines and is expected to be a significant contributor to Antigenics future royalty income in the event of successful commercialization." QS-21 is a key component in several of GSK"s proprietary adjuvant systems, which play an integral role in a new generation of GSK vaccines currently in development. Under the terms of the license and supply agreements announced in July 2006, GSK will make payments contingent upon successful milestone achievements, and will pay royalties to Antigenics on net sales for a period of at least 10 years after first commercial sale. Recent Phase 2 malaria studies showed that, over an eight-month follow-up period, RTS,S reduced clinical episodes of malaria by 53 percent and had a promising safety and tolerability profile when used alongside standard infant vaccines. The Phase 3 trial builds on more than 10 years of clinical research in Africa, including the first proof-of-concept study in children in 2004 and a proof-of-concept study in infants in 2007. If the RTS,S Phase 3 program progresses as expected, RTS,S could be submitted for initial regulatory review in 2011. If the required regulatory clearances are granted and international and African national public health authorities recommend its use, RTS,S could be introduced in 2012 for children age 5-17 months. Following recommendations for use in infants, full availability is anticipated by 2014, potentially saving hundreds of thousands of lives a year. About QS-21 Stimulon Adjuvant Antigenics" QS-21 Stimulon adjuvant is one of the most widely tested vaccine adjuvants under development. QS-21 has not only become a critical component in the development of preventative vaccine formulations across a wide variety of infectious diseases, but may also be essential in enabling a new generation of therapeutic vaccines to treat cancer, infectious diseases and degenerative disorders. QS-21 is currently being evaluated in approximately 20 vaccine indications, of which several are in late-stage clinical trials by Antigenics" licensees, including GlaxoSmithKline and Elan. Antigenics Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009